Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1981 2
1982 1
1983 1
1984 2
1985 3
1986 8
1987 5
1988 17
1989 22
1990 34
1991 46
1992 69
1993 104
1994 125
1995 96
1996 151
1997 158
1998 162
1999 179
2000 163
2001 189
2002 228
2003 268
2004 287
2005 275
2006 305
2007 348
2008 345
2009 346
2010 514
2011 553
2012 624
2013 686
2014 790
2015 858
2016 975
2017 1051
2018 1032
2019 1145
2020 1187
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

11,975 results
Results by year
Filters applied: . Clear all
Page 1
Translating the biology of aging into novel therapeutics for Alzheimer disease.
Hara Y, McKeehan N, Fillit HM. Hara Y, et al. Neurology. 2019 Jan 8;92(2):84-93. doi: 10.1212/WNL.0000000000006745. Epub 2018 Dec 7. Neurology. 2019. PMID: 30530798 Free PMC article. Review.
Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer disease (AD), a progressive neurodegenerative disease with currently no therapies that prevent, slow, or halt disease progression. ...
Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer disease (AD), a progressive neurod …
Female Sex and Alzheimer's Risk: The Menopause Connection.
Scheyer O, Rahman A, Hristov H, Berkowitz C, Isaacson RS, Diaz Brinton R, Mosconi L. Scheyer O, et al. J Prev Alzheimers Dis. 2018;5(4):225-230. doi: 10.14283/jpad.2018.34. J Prev Alzheimers Dis. 2018. PMID: 30298180 Free PMC article. Review.
Along with advanced age and apolipoprotein E (APOE)-4 genotype, female sex is a major risk factor for developing late-onset Alzheimer's disease (AD). Considering that AD pathology begins decades prior to clinical symptoms, the higher risk in women cannot simp …
Along with advanced age and apolipoprotein E (APOE)-4 genotype, female sex is a major risk factor for developing late-onset Alzheimer
Role of epigenetics in Alzheimer's disease pathogenesis.
Stoccoro A, Coppedè F. Stoccoro A, et al. Neurodegener Dis Manag. 2018 Jun;8(3):181-193. doi: 10.2217/nmt-2018-0004. Epub 2018 Jun 11. Neurodegener Dis Manag. 2018. PMID: 29888987 Review.
Advances in molecular biology technologies have allowed uncovering the role of epigenetic regulation in several complex diseases, such as cancer and neurodegenerative disorders. Although the role of epigenetic mechanisms in Alzheimer's disease is still little …
Advances in molecular biology technologies have allowed uncovering the role of epigenetic regulation in several complex diseases, such as ca …
While I Still Remember: 30 Years of Alzheimer's Disease Research.
Shea TB. Shea TB. J Alzheimers Dis. 2018;62(3):1049-1057. doi: 10.3233/JAD-170724. J Alzheimers Dis. 2018. PMID: 29226872 Free PMC article. Review.
Turns out I have been a major contributor to the Journal of Alzheimer's Disease over its 20-year history. As such, I was invited to provide a review of my work over the years. What follows is a retrospective of how the Alzheimer-related research of a P …
Turns out I have been a major contributor to the Journal of Alzheimer's Disease over its 20-year history. As such, I wa …
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?
Raikwar SP, Thangavel R, Dubova I, Ahmed ME, Selvakumar PG, Kempuraj D, Zaheer S, Iyer S, Zaheer A. Raikwar SP, et al. J Alzheimers Dis. 2018;65(2):321-344. doi: 10.3233/JAD-180422. J Alzheimers Dis. 2018. PMID: 30040732 Free PMC article. Review.
Alzheimer's disease (AD) is a highly complex neurodegenerative disorder and the current treatment strategies are largely ineffective thereby leading to irreversible and progressive cognitive decline in AD patients. ...
Alzheimer's disease (AD) is a highly complex neurodegenerative disorder and the current treatment strategies are largel
The Involvement of Post-Translational Modifications in Alzheimer's Disease.
Marcelli S, Corbo M, Iannuzzi F, Negri L, Blandini F, Nistico R, Feligioni M. Marcelli S, et al. Curr Alzheimer Res. 2018 Feb 22;15(4):313-335. doi: 10.2174/1567205014666170505095109. Curr Alzheimer Res. 2018. PMID: 28474569 Review.
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder recognized as the most common cause of chronic dementia among the ageing population. ...Several recent studies show that AD-related proteins like APP, Abeta, tau, BACE1 undergo post-trans
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder recognized as the most common cause of chronic dem …
Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik C, Hof PR. Šimić G, et al. Biomolecules. 2016 Jan 6;6(1):6. doi: 10.3390/biom6010006. Biomolecules. 2016. PMID: 26751493 Free PMC article. Review.
Abnormal deposition of misprocessed and aggregated proteins is a common final pathway of most neurodegenerative diseases, including Alzheimer's disease (AD). AD is characterized by the extraneuronal deposition of the amyloid beta (Abeta) protein in the …
Abnormal deposition of misprocessed and aggregated proteins is a common final pathway of most neurodegenerative diseases, including Alzhe
Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health.
Vega IE, Cabrera LY, Wygant CM, Velez-Ortiz D, Counts SE. Vega IE, et al. J Alzheimers Dis. 2017;58(4):979-992. doi: 10.3233/JAD-161261. J Alzheimers Dis. 2017. PMID: 28527211 Free PMC article. Review.
Alzheimer's disease (AD) is the most common type of dementia among individuals 65 or older. ...
Alzheimer's disease (AD) is the most common type of dementia among individuals 65 or older. ...
Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.
Mullane K, Williams M. Mullane K, et al. Curr Protoc Pharmacol. 2019 Mar;84(1):e57. doi: 10.1002/cpph.57. Epub 2019 Feb 25. Curr Protoc Pharmacol. 2019. PMID: 30802363 Review.
The only drugs currently approved for the treatment of Alzheimer's Disease (AD) are four acetylcholinesterase inhibitors and the NMDA antagonist memantine. ...This overview discusses the current animal models of AD in the context of both the controversies sur …
The only drugs currently approved for the treatment of Alzheimer's Disease (AD) are four acetylcholinesterase inhibitor …
The Alzheimer Precision Medicine Initiative.
Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121. J Alzheimers Dis. 2019. PMID: 30814352 Review.
PM is defining which therapeutic approach will be the most effective for a specific individual, at a determined disease stage, across multiple medical research fields, including neuroscience, neurology and psychiatry. The launch of the Alzheimer Precision Medicine I …
PM is defining which therapeutic approach will be the most effective for a specific individual, at a determined disease stage, across …
11,975 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback